A First-in-human, Dose Escalation and Indication Expansion Study of BNT3212 as Monotherapy or in Combination With BNT327 in Adults With Advanced Solid Tumors

This study is testing a new cancer immunotherapy drug called BNT3212, either alone or combined with another drug (BNT327), in adults with advanced solid tumors. It is a first-in-human study, meaning this drug is being tested in people for the first time. **You may be eligible if...** - You are an adult with a confirmed advanced, recurrent, or metastatic solid tumor - Your cancer has progressed after at least one standard treatment, or standard treatment is not suitable for you - You have at least one measurable tumor - You are in relatively good physical condition (ECOG status 0 or 1 — fully active or able to do light activity) - Your expected life expectancy is at least 3 months - Your heart function is adequate **You may NOT be eligible if...** - Your cancer has spread to the brain and is untreated - You have significant organ dysfunction or unstable health conditions Talk to your doctor to see if this trial is right for you.